key: cord-0869486-9ke3iq81
authors: Das, Parijat; Mondal, Sudipto; Pal, Soumik; Roy, Samadrita; Vidyadharan, Anju; Dadwal, Rajneesh; Bhattacharya, Sanjay; Mishra, Deepak Kumar; Chandy, Mammen
title: COVID diagnostics by molecular methods: A systematic review of nucleic acid based testing systems
date: 2021-06-10
journal: Indian J Med Microbiol
DOI: 10.1016/j.ijmmb.2021.05.012
sha: 40112f0799f14e4a66ab8127005b459a8fcd1d38
doc_id: 869486
cord_uid: 9ke3iq81

BACKGROUND: The selection of appropriate kit and PCR equipment for the detection of SARS CoV-2 is critically important in view of many options available in the diagnostic market. Since last year many molecular products are available for COVID-19 diagnostics., some of these diagnostics have become commercially available for healthcare workers and clinical laboratories. However, the diagnostic technologies have specific limitations and reported several false-positive and false-negative cases, especially during the early stages of kit development and use. The current article addresses these and other relevant questions important to the medical microbiologists running or aspiring to run COVID diagnostic services using PCR and related technologies. METHODS: In this Systematic Review we follow Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA). A total of 258 citations retrieved, among those 77 peer reviewed articles was assessed for eligibility, and 181 studies were excluded. Based on inclusion criteria final data extraction was done. RESULTS: The question of diagnostic dilemma has also been addressed in view of discordant results between assays, inter-test variability, repeat testing requirements in specific settings and inconclusive or indeterminate results. Kit efficiency was satisfactory for all assays and the estimates varied within sample types and technology. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona) viruses, except as expected for the SARS-CoV-1 E-gene. CONCLUSIONS: We conclude SARS CoV-2 related molecular assays differed considerably in performance. Hence we need to understand importance of molecular diagnostics test interpretation in light of the latest pandemic virus.

The COVID pandemic which started in 2019 has been defined by extensive use of reverse transcriptase real time polymerase chain reaction as a diagnostic modality. Since many infections are pauci-symptomatic and asymptomatic accurate testing is very important [1] . Early accurate diagnosis of COVID facilitates better management in terms of timely hospital admission, initiation of specific anti-viral agents such as remdesivir and infection control measures. The symptoms of COVID are quite similar to that of common flu (influenza); [2] therefore, it is difficult to distinguish the difference between SARS-CoV-2 and common flu.

Although the number of COVID tests done in India have steadily increased there is a need to test more considering the enormity of India's population (1.3 billion) and surge of cases due to the second wave of the pandemic in the country. This article mainly concentrates on the current scenario in India regarding molecular based testing for COVID-19 infection. It covers the types of RT-PCR based molecular tests, test kits. The objective of this review is to help and inform health care service providers and health administrators about RT-PCR based COVID tests and optional strategies for selection of select equipment for such test.

This Systematic Review was conducted following Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) requirement and Cochrane Collaboration recommendations.

The literature search criteria for this study was divided in two category. In

Step-1 we searched PubMed and Google Scholar regarding abstracts and manuscripts using key words: "COVID-19 detection" OR "COVID-19" AND "COVID-19 CBNAAT," and "COVID-19" AND "RT-PCR" AND "COVID-19" AND "PCR". In Step-2: public web portal based information (ICMR-Indian Council of Medical Research, Government of India, World Health Organization, CDSCO (Central Drugs Standard Control Organization), FIND (Foundation for Innovative New Diagnostics) web portal) were searched. In this case we only considered company based validation data because in some cases there was no proper study published till date. All data were considered between January to September 2020. We searched the website of Foundation for Innovative New Diagnostics (FIND)-a global non-profit organization website. FIND is a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation platform. Information based on FIND's all Real-Time PCR kits which are US-FDA can be used for lab diagnosis in India after due marketing approval from DCGI (The Drugs Controller General of India). Search criteria (key words) for searching FIND web portal https://www.finddx.org/included: "commercialized", "Test format", "manual NAAT" or "automated", "POC", "NAT" or "POC" "NAAT", "Regulatory", "CE IVD" or "INDIA", "CDSCO" or "US FDA" or "RUO" (Research use only). This study also searched performance evaluation of commercial kits for real time PCR for COVID as done by ICMR validation centres whose report was published by Indian Council of Medical Research, Government of India. https://www.icmr.gov.in/pdf/co vid/kits/RT_PCR_Tests_Kits_Evaluation_Summ_21012021.pdf.

Step-1 we searched Pubmed and Google Scholar #In Step-2 public web portal based information (ICMR Govt of India, WHO, DCGI recognized kits, FIND web portal).

The eligibility criteria for included studies were as follows: 

Data extraction was done using a data extraction form that was designed and pilot tested a priori. Two authors (PD and SB) independently extracted the following information from each study: author year, country, study design, setting (hospital or diagnostic laboratory), method of recruitment, inclusion criteria, risk of bias, participants (technology, sample tested, final outcome), intervention (turnaround time, cost, throughput, and co-intervention if any), outcomes, loss to followup and key conclusions. Any disagreements between the two review authors were resolved through discussion with the third author (SM).

Of 258 total citations retrieved, the full text of 77 papers was assessed for eligibility, and 181 studies were excluded [supplementary].

Coronaviruses are un-segmented single-stranded RNA viruses ranging from 26 to 32 kilobases in length, belonging to the subfamily Coronavirinae of the family Coronaviridae of the order Nidovirales [3] . The genome of Coronaviruses, includes a variable number of open reading frames (ORFs) [4] . The SARS-CoV-2 genome was reported to possess 14 ORFs encoding 27 proteins [5] . The spike surface glycoprotein (S) plays an essential role in binding to receptors on the host cell and is crucial for determining host tropism and transmission capacity, mediating receptor binding and membrane fusion [6] . Generally, the spike protein of Coronaviruses is functionally divided into the S1 domain, responsible for receptor binding, and the S2 domain, responsible for cell membrane fusion [7] .The eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b, and orf14) and four major structural proteins, including the spike surface glycoprotein (S), small envelope protein (E), matrix protein (M), and nucleocapsid protein (N), are located in the 3 0 -terminus of the SARS-CoV-2 genome [5] .

Sensitive, specific, precise and accurate reliable diagnostic kits and reagents are of paramount importance for combating the ongoing COVID-19 pandemic. The World Health Organization has recommended reverse transcription-polymerase chain reaction (RT-PCR) for screening and confirmation of COVID-19 [9] . Most of the national and international commercial kit manufacturers select these genes for different platform of RT-PCR. Table 2 shows different gene targets available in different PCR kits.

There are currently 4 testing methodologies to clinically detect viral disease:

1. Real-Time PCR: manual or Cartridge Based Nucleic Acid Amplification Test (CBNAAT) format 2. Isothermal Amplification 3. CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats) 4. Serological IgM/IgG Antibody Detection (not discussed in this review) 5. Viral Antigen Detection (not discussed in this review)

Directly detects for viral RNA by molecular methods High specificity, sensitivity, positive and negative predictive values

Instrument, consumable and reagent costs are much higher than most laboratory assays Needs personnel trained in molecular testing. Labour intensive and less automated in comparison to other laboratory tests (e.g. serology) Turn Around Time: Conventional RT-PCR testing may take up to 4-6 h to obtain results including time for nucleic acid extraction Requires additional lab equipment, consumable supply, and reagents for nucleic acid extraction.

Conventional RT-PCR requires separate rooms, equipment, and safety cabinets to prevent nucleic acid contamination between setup, amplification, and reading. Sensitivity is greatly affected by proper specimen collection False negative may occur with: inadequate swabbing of the appropriate target region where virus resides; timing of sample collection; improper shipping/storage conditions; mutation in the region of gene target

In Table 3 examples of isothermal amplification techniques for nucleic acids include:

Loop mediated isothermal amplification Strand displacement amplification Nucleic Acid Sequence Based Amplification Helicase Dependent Amplification Recombinase Polymerase Amplification SMART-Simple Method to Amplify RNA Targets

High specificity and sensitivity. Instrumentation has a small footprint and are inexpensive and simple to use in comparison to real-time PCR equipment Extra equipment like DNA/RNA extraction not required Rapid method: Denaturation/annealing/amplification steps are performed at one temperature instead of the heating and cooling steps required in real-time PCR. Thus, reducing the time-to-result for many assays. Results can be as rapid as within 30 min. Requires less manual labor than most other molecular assays.

Reagent costs per sample are much higher than most real-time PCR assays Not recommended for high-throughput environments as batch testing is not available; most instrumentation can only run 1 sample at a time. Limited versatilityonly short gene targets can be amplified; thus, variety of different assays available to run on these technologies are very narrow and limited in scope in comparison to real-time PCR Sensitivity is greatly affected by proper specimen collection.

The technology is based on gene editing It has programmable ability to detect specific sequences of DNA within a gene of interest The method can subsequently cut the gene at a specific sequence using an enzyme which act as a molecular scissors CRISPR can operate as a diagnostic tool for detecting specific sequences of DNA/RNA such as those that uniquely exist in the SARS-CoV-2 virus CRISPR-based POCT (point of care tests), specifically for rapid Covid-19 diagnosis has been developed by SHERLOCK biosciences

The rapid diagnosis of coronavirus disease 2019 (COVID-19) is a significant step towards the containment of the virus. Cartridge Based Nucleic Acid Amplification Test (CBNAAT) platforms like Cepheid Xpert Xpress SARS CoV-2, that employ real time RT PCR technology, are in use for COVID-19 testing in India. TRUENAT SARS CoV-2 is a chip-based Real-time Reverse transcription Polymerase Chain Reaction (RT-PCR) test for the semi-quantitative detection of SARS CoV-2 RNA. TRUENAT system has been validated by ICMR and Cepheid Xpert Xpress SARS CoV-2 has been approved by US FDA for use under an emergency use authorization. Initially TRUENAT Beta CoV was used for screening assay and TRUENAT SARS-CoV-2 used for confirmation assay as a PoC basis for the detection of SARS-CoV-2. Subsequently a single assay has been developed by TRUENAT however with a CT cut-off of 32.

For CE-IVD approved/Non US-FDA approved/USA EUA/Indigenous Kits: First batch of kits will require validation from any of nine direct ICMR validation centres or any other 15 DBT/CSIR/other affiliated institute prior to DCGI approval. In the post marketing phase additional two batches should be tested as per medical device rule in four months time [10] . In India, as per ICMR guideline any RT-PCR kits approved by US-FDA need not require additional validation.

(i) Interpretation of molecular results.

As per CDC initial protocol the laboratory confirmatory criteria for COVID-19 positive cases was detection of both of two targets in the CDC assay (nucleocapsid proteins N1 and N2 had to be positive) [11] . A cycle threshold (CT) value of less than 40 was defined as a positive test, while a CT value of 40 or more was defined as a negative test. A CT value of less than 40 for only one of the two nucleocapsid protein (N1 and N2) was defined as indeterminate (inconclusive) and required confirmation by retesting the test [11] . In triplex assays with three targets (Table 1) , positives for two or more targets are considered positive [12] . Viral loads Table 3 Isothermal DNA Amplification Technologies compared to PCR (a non isothermal method). Sometimes the borderline cases just over the cut-off may be called positive or vice versa The discrepancy is likely to be less with low CT values (CT < 35); and significantly more after that (CT > 35 or low viral load situation) Also note CT values may be affected by all the factors mentioned as above. Some experts are of the view that as COVID is a new disease with no proven anti-viral treatment or vaccine, reporting borderline situation as positive is perhaps safer than doing it otherwise determined by real-time RT-PCR assays should not be used to indicate COVID-19 severity or to monitor therapeutic response [13] [14] [15] . However, low RT-PCR CT values signifying high viral loads may be used as an indication of transmissibility.

(ii) COVID infectivity: time dependence, symptom dependence, clinical phenotype dependence and RT-PCR CT value dependence Infectivity duration of symptomatic and asymptomatic COVID patients is a matter of concern for patients, care givers, healthcare providers and public health. In a study from the virus reference laboratory at Colindale UK it was reported that the probability of culturing virus declined to 8% in samples with CT > 35 and to 6% 10 days after onset; it was found to be similar in asymptomatic and symptomatic persons [16] . A study from the University of Nebraska reported that, viable virus was rarely cultured at CT values > 30 on or after 14 days of illness, suggesting that the probability of infectivity decreased with increasing CT values [17] . A study from the virus reference lab at Ireland reported that COVID-19 patients with mild-to-moderate illness were highly unlikely to be infectious beyond 10 days of symptoms. SARS-CoV-2 was isolated beyond day 10 for approximately 3% of included patients. Two studies identified immunocompromised patients from whom SARS-CoV-2 was isolated for up to 20 days. Three virus culture studies included patients with severe or critical disease; SARS-CoV-2 was isolated in these critically ill patients for up to day 32 in one study [18] . A study from the Harvard University reported that SARS-CoV-2 appeared to be most contagious around the time of symptom onset, and infectivity rapidly decreased thereafter to near-zero after about 10 days in mild/moderately ill patients and 15 days in severely-critically ill and immunocompromised patients. The longest interval associated with replication-competent virus thus far is 20 days from symptom onset [19] . An European study looking at correlation between successful isolation of virus in cell culture and CT value of quantitative RT-PCR targeting E gene suggested that patients with CT above 33-34 using RT-PCR system were not contagious and thus may be discharged from hospital care or strict confinement for non-hospitalized patients [20] .

The qualitative real-time PCR interpretation of SARS-CoV-2 from patient is mainly relying on three possible reporting outcomes: Positive, Negative and Inconclusive. If the internal control for extraction/PCR (IC) was not amplified repeat extraction and RT-PCR should be considered. Inconclusive results may also happen if only the E gene is positive. There are multiple reasons which may cause inconclusive results for COVID-19 RT-PCR assay (Table 3 ). In this review we are try to highlight some of the possible causes for inconclusive result with respect to COVID-19 RT-PCR assay. In a communication dated April 05, 2021 ICMR issued an advisory stating that with regard to RT_PCR assays for SARS-CoV-2 a CT value cutoff of 35 with a good sigmoidal real-time RTPCR curve is acceptable. All patients with a Ct value < 35 may be considered as positive while those with Ct value > 35 may be considered as negative. All samples with CT value < 35 with poor sigmoidal curves should be essentially re-tested. The advantages and disadvantages of this advisory may be summarized as follows: [22] . Faced with sudden increase in sample throughput demand combined with unprecedented urgency, the challenges of scaling up nucleic acid isolation kits can often become overwhelming. Till date there are few comparative analysis done for COVID-19 RNA extraction and performance with respect to robotic automated systems and manual system (see Table 4 ). Table 5 compares most of the self-enclosed systems (CBNAAT) integrating nucleic acid extraction, amplification and detection which play a major role in point-of-care testing for hospitals and clinics without the need of a comprehensive molecular biology laboratory [23] . QIAstat-Dx by Qiagen, Germany is a multiplex syndromic cartridge based detection system which differentiates 22 respiratory targets, including SARS-CoV-2 from Nasopharyngeal swabs.

The present commercial kit available in the Indian market may be categorized based on the number of tube per sample reaction, number of gene targets, number of samples which may be tested within a given run (this may be determined by the number of tubes per sample), RT-PCR instrument compatibility, reporter dye for each of the gene target, PCR time, pack size of the kits, reaction volume, price of the kit, supply chain flow. Among the made in India kits for COVID, Mylab Discovery Solutions (PathoDetect) was the first to be available commercially. This kit comprised of RdRp, E gene and RNAseP as internal control. The major disadvantage of this version 1 kit from MyLab was the fact that it was not a single tube test. One could process only 30 samples at a given time in a typical 96 well plate format. This increased the workload and time significantly, as well as possibility of error. On the other hand a kit developed by BlackBio Biotech (True-PCR) which has a single tube format required significantly less time (1.3hrs) to produce PCR results.

The studies were variable in many aspects (blinding of participants and outcome assessment, technology selection, sensitivity/specificity of the assay, kit format, number of targeted genes, chemistry of assay, timing of assay etc.

Early detection of symptomatic as well as asymptomatic SARS-CoV-2 infections and reduction of transmission rates is critical to prevent and manage any outbreaks, and is pivotal for the prevention of COVID-19 pandemic. Real-time polymerase chain reaction (RT-PCR) is the gold standard among the early detection methods for COVID-19. In this systematic review we have attempted to collate the information about molecular based detection of COVID-19. Our success to tackle the pandemic effectively will depend on our ability to use the kits, machines and protocols effectively. 

Prevalence of asymptomatic SARS-CoV-2 infection

Q&A: Influenza and COVID-19 -similarities and differences

Advances in Virus Research

From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe

Predicting the receptor-binding domain usage of the coronavirus based on kmer frequency on spike protein

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine

Diagnosing COVID-19: the disease and tools for detection

Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India

Guidelines for validation and batch testing OF COVID-19 diagnostic kits department OF health research ministry OF health and family welfare. GOVERNMENT OF INDIA ICMR-DCGI

First case of 2019 novel coronavirus in the United States

Chinese guidelines related to novel coronavirus pneumonia

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Viral load of SARS-CoV-2 in clinical samples

Well Infant With Coronavirus Disease 2019 With High Viral Load j Clinical Infectious Diseases j Oxford Academic

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Evaluation of cycle threshold values at deisolation

The duration of infectiousness of individuals infected with SARS-CoV-2

Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin Infect Dis an Off Publ Infect Dis Soc Am

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

RNA isolation and real-time quantitative RT-PCR

Information For Testing Laboratory

The laboratory diagnosis of COVID-19 infection: current issues and challenges 1 2 3 Downloaded from

This study was not funded by any government agency or any funding agencies, this study only funded by the institutional fund

Supplementary data to this article can be found online at https:// doi.org/10.1016/j.ijmmb.2021.05.012.